文献速递临床微生物分子诊断

GenMark Dx ePlex 血培养鉴定革兰阴性菌面板的多中心临床诊断准确性研究

A Multicenter Clinical Study To Demonstrate the Diagnostic Accuracy of the GenMark Dx ePlex Blood Culture Identification Gram-Negative Panel.
PubMed 文献 · J Clin Microbiol · 2021-08-18

该多中心临床研究评估了 GenMark Dx ePlex 血培养鉴定革兰阴性菌面板(BCID-GN)在阳性血培养瓶中的诊断性能。研究纳入 2,444 份阳性血培养样本,其中 926 份为革兰染色阴性的临床样本,总体样本准确率为 88.2%(817/926),经不一致结果解析后升至 92.9%(860/926),27 个靶标的总体加权阳性符合率为 94.9%。

要点

  • BCID-GN 对革兰阴性菌及耐药基因的总体加权阳性符合率为 94.9%。
  • 在革兰染色阴性临床样本中,初始准确率为 88.2%,解析后为 92.9%。
  • 检测限范围为 10^4 至 10^7 CFU/ml,一株坏死梭杆菌为 10^8 CFU/ml。

核心结论

  • BCID-GN 面板可快速鉴定阳性血培养中的革兰阴性菌及耐药基因,整体准确性较高。

研究设计与样本

  • 多中心临床研究,检测前瞻性、回顾性及人工构建样本,结果与标准细菌鉴定方法比较。
  • 最终分析纳入 2,444 份阳性血培养样本,其中 926 份为革兰染色阴性的临床样本。

主要发现

  • 926 份革兰染色阴性临床样本中,109 份出现假阴性或假阳性,总体样本准确率为 88.2%(817/926)。
  • 经不一致结果解析后,总体样本准确率提高至 92.9%(860/926)。
  • 27 个靶标(革兰阴性菌及耐药基因)的总体加权阳性符合率为 94.9%。
  • 检测限范围为 10^4 至 10^7 CFU/ml,一株坏死梭杆菌为 10^8 CFU/ml。

关键数值与推荐

  • 总体加权阳性符合率(PPA)为 94.9%,基于 27 个靶标个体 PPA 的平均值。
  • 革兰染色阴性临床样本初始准确率 88.2%(817/926),解析后 92.9%(860/926)。
  • 检测限 10^4–10^7 CFU/ml,坏死梭杆菌一株为 10^8 CFU/ml。

临床怎么用

  • BCID-GN 可用于阳性血培养的快速病原体鉴定和耐药基因检测,辅助临床尽早调整抗菌治疗。

局限性

  • 研究未涵盖 BCID-GN 靶标外的微生物,包括 37 种革兰阴性菌(20 个不常见属)、10 种革兰阳性菌和 1 种念珠菌,这些占样本的 5%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bacteremia can progress to septic shock and death without appropriate medical intervention. Increasing evidence supports the role of molecular diagnostic panels in reducing the clinical impact of these infections through rapid identification of the infecting organism and associated antimicrobial resistance genes. We report the results of a multicenter clinical study assessing the performance of the GenMark Dx ePlex investigational-use-only blood culture identification Gram-negative panel (BCID-GN), a rapid diagnostic assay for detection of bloodstream pathogens in positive blood culture (PBC) bottles. Prospective, retrospective, and contrived samples were tested. Results from the BCID-GN were compared to standard-of-care bacterial identification methods. Antimicrobial resistance genes (ARGs) were identified using PCR and sequence analysis. The final BCID-GN analysis included 2,444 PBC samples, of which 926 were clinical samples with negative Gram stain results. Of these, 109 samples had false-negative and/or -positive results, resulting in an overall sample accuracy of 88.2% (817/926). After discordant resolution, overall sample accuracy increased to 92.9% (860/926). Pre- and postdiscordant resolution sample accuracy excludes 37 Gram-negative organisms representing 20 uncommon genera, 10 Gram-positive organisms, and 1 Candida species present in 5% of samples that are not targeted by the BCID-GN. The overall weighted positive percent agreement (PPA), which averages the individual PPAs from the 27 targets (Gram-negative and ARG), was 94.9%. The limit of detection ranged from 104 to 107 CFU/ml, except for one strain of Fusobacterium necrophorum at 108 CFU/ml.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Wolk DM, Young S, Whitfield NN, et al. A Multicenter Clinical Study To Demonstrate the Diagnostic Accuracy of the GenMark Dx ePlex Blood Culture Identification Gram-Negative Panel. J Clin Microbiol. 2021. PMID: 34232066. doi:10.1128/JCM.02484-20

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。